Nuclear phosphoprotein 32 (pp32) inhibits K-ras induced transformation in experimental models. pp32 mRNA expression correlates with differentiation status in breast and prostate cancers. In this study, we evaluated pp32 protein expression in relation to the differentiation status of pancreatic ductal adenocarcinomas and precursor lesions of the pancreatic cancers. pp32 expression showed strong nuclear staining in normal pancreatic acini and ducts. The intensity of this staining was maintained in pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasms with mild dysplasia, well-differentiated adenocarcinomas, and in a subset of moderately differentiated adenocarcinomas. pp32 staining was absent or reduced in poorly differentiated tumors and in intraductal papillary mucinous neoplasms with moderate dysplasia. We validated pp32 expression by a second technique, immunoblot analysis of lysates from resected pancreatic ductal adenocarcinomas and pancreatic cancer cell lines. The well-differentiated pancreatic cancer cell line HPAC expressed high amounts of pp32, as compared to the poorly differentiated pancreatic cancer cell lines MiaPaCa2, Pl19, and Pl21 cells. Artificial introduction of pp32 expression into a poorly differentiated cell line, MiaPaCa2, caused an increase in G1 arrest compared to control cells. On the basis of this study and previous functional work that shows pp32 can inhibit K-ras transformation, we propose that reduction in pp32 expression levels may be a critical event in the progression of pancreatic tumorigenesis in an aggressive subset of pancreatic ductal adenocarcinomas. Keywords: pancreatic ductal adenocarcinoma; pp32 (ANP32A); protein expression; tumor suppressor; poorly differentiated pancreatic adenocarcinomas; intraductal papillary mucinous neoplasms
Little is known about the molecular basis of poorly and undifferentiated pancreatic ductal adenocarcinomas, the most aggressive type of pancreatic cancer. We studied pp32 (also known as ANP32A) protein expression in pancreatic cancers because it has been shown to directly relate to the differentiation status of cancers in other systems and because previous functional work predicts a connection of pp32 to pancreatic tumorigenesis. 1, 2 pp32 is a multifunctional nuclear phosphoprotein that inhibits oncogene-mediated transformation in cell culture. [3] [4] [5] In relation to specific molecular aspects of pancreatic tumorigenesis, pp32 has been shown to inhibit a K-ras activating mutation, found in over 90% of pancreatic ductal adenocarcinomas, in both in vitro and in vivo models. 3, 5 Specifically K-ras dependent tumor formation in vivo is inhibited by pp32 overexpression and accelerated when pp32 expression is ablated. 5 Moreover, pp32 was shown to bind to the phosphorylated form of Rb which is the dysregulated form of Rb found in nearly all pancreatic cancers due to p16 inactivation. 6, 7 Other pp32 functions related to tumorigenesis have been described and may explain why pp32 can inhibit K-ras signaling. pp32 has been shown to cooperate with Hur in stabilizing critical tran-scripts. 8 It is believed that Hur plays a critical role in tumorigenesis. 9 Further, pp32 has also been shown to form a complex that inhibits histone acetylation as part of the INhibitor of Histone Acetyl Transferase (INHAT) complex, and thus pp32 may help to regulate or repress transcriptional events critical for proliferation and tumorigenesis. 10, 11 pp32 mRNA expression has been studied in other epithelial tumor systems. In benign prostatic tissues, moderate pp32-related mRNA expression occurs only in the basal cells. 1, 12 A study of prostatic adenocarcinomas found elevated pp32 expression in 98% (54/55) of adenocarcinomas of Gleason score Z5 (Po0.0001).
1 A follow-up study investigated pp32-related mRNA expression in human breast cancer. In breast cancer, abundant pp32-related mRNA expression was found in benign ducts and acini and in infiltrating ductal carcinomas. A total of 100/102 cases were positive for pp32 expression. pp32's role in differentiation was functionally established when it was shown that long-term manipulated reduction of pp32 expression in the bladder carcinoma cell line, TSU-Pr1, induced neuronal differentiation. 13 Taken together, pp32 expression appears to be a critical molecular marker and direct determinant of the state of differentiation in epithelial cancers. To date, pp32 expression has not been studied in normal pancreas and pancreatic ductal adenocarcinomas. The goal of this study was to correlate the differentiation status of pancreatic ductal adenocarcinomas with pp32 protein expression and to study the effect of manipulating pp32 expression in poorly differentiated pancreatic cancer cells.
Materials and Methods

Specimens
Thirty-five cases of pancreatic adenocarcinomas, five cases of pancreatic intraepithelial neoplasia and four cases of intraductal papillary mucinous neoplasms were retrieved from the Thomas Jefferson University pathology archives. The adenocarcinoma cases included 10 well, 15 moderately, and 10 poorly differentiated tumors. For three tumors, lymph node metastases were included in the analysis. Two pancreatic intraepithelial neoplasia-1, three pancreatic intraepithelial neoplasia-3, and four intraductal papillary mucinous neoplasms (two with mild and two with moderate dysplasia) were also examined. This study was approved by the Institutional Review Board of the Thomas Jefferson University.
Immunohistochemistry
Formalin-fixed, paraffin-embedded blocks were processed for immunohistochemical analysis using heat antigen retrieval and avidin-biotin complex technique. pp32 antibody was applied to slides and incubated for 60 min using a 1/200 dilution (see description of the pp32 antibody in the next section). Staining intensity was scored blindly as strong, weak, or negative on the basis of nuclear staining. Weak cytoplasmic staining or reactivity in rare cells (o5%) was interpreted as negative. The staining pattern was scored as diffuse or focal based on the percentage of tumor cells staining (470 vs 5-70%, respectively).
Immunoblot Analysis
Cells were lysed with an SDS-lysis buffer. A measure of 5-20 mg of protein per well was separated by electrophoresis for over 2 h at 200 V using 10% bis-tris-polyacrylamide gels (Invitrogen, Carlsbad, CA, USA). After electrophoretic transfer of proteins on to polyvinylidene difluoride membranes, they were sequentially blocked in Tris-buffered saline/ 0.5% Tween (TBS-T)/5% milk, incubated with primary pp32 antibody (1:1000) and then incubated with a horseradish peroxidase-conjugated secondary antibody (1:20 000, GE Healthcare, Piscataway, NJ, USA). 4 The production of pp32 antibody was described previously. 4, 14 The protein bands were visualized on X-ray film using the Immobilon Western Chemiluminescent Substrate (Millipore, Billerica, MA, USA). Fast Green stain was used to stain the membrane to validate equal protein loaded per well (USB, Cleveland, OH, USA). At least two experiments were performed for each data point, and representative data are shown.
Cancer Cell Lines
Cancer cell lines were maintained in DMEM (low glucose, Invitrogen) containing 10% FBS, 1% pen./ strep., and 1% L-glutamine. Pl19 and Pl21 cell lines were donated to us by Dr Elizabeth Jaffee (Johns Hopkins University, Baltimore, MD, USA). All other pancreatic cancer cell lines (MiaPaCa2, HPAC, XPA1, and Su86.86) were donated by Dr Scott Kern (Johns Hopkins University, Baltimore, MD, USA).
Transfection of Pancreatic Cancer Cells
The pp32 cDNA sequence was cloned into the pcDNA3.1Zeo þ vector (Invitrogen) to obtain optimal expression post transfection. Stable transfection of MiaPaCa2 cells were performed using Lipofectint reagent (Invitrogen). Equal cells were plated in T-75 flasks and were transfected at 40-50% confluency using 10 mg of 32.CMV (sense-pp32 construct) or EV.CMV (empty vector). In brief, cells were maintained in a transfection mix with Lipofectin reagent for 5 h and then replenished with standard DMEM high glucose media with 10% FBS and 1% pen./ strep. and were allowed to recover for 72 h. Cells were then trypsinized and replated in equal numbers into six-well plates and T-75 plates and the selection was done with 50 mg/ml of zeocin, as determined by an antibiotic kill curve. Selection took place over several weeks to allow for the plasmids to integrate into the cells.
Cell Cycle Studies
Overexpressing pp32 MiaPaCa2 cells (Mia.32) and empty vector stably transfected cells (Mia.EV) were plated equally into T-75 flasks and grown to confluency. Adherent cells were trypsinized and collected for staining using propidium iodide (PI). In brief, cells were fixed in ethanol and placed in a PI-staining solution containing 20 mg/ml PI, 100 mg/ ml RNase A, and 0.1% Triton X-100 (Sigma, St Louis, MO, USA). Cell cycle analysis was subsequently performed using flow cytometry and analyzed with the System II software (Beckman, Fullerton, CA, USA).
Results
pp32-Specific Expression in Pancreatic Tissue
By immunohistochemistry pp32 exhibited strong nuclear staining in normal pancreatic acini and ducts ( Figure 1a ). Variable nuclear reactivity for pp32 was identified in all cases of pancreatic ductal adenocarcinomas. Ten well differentiated and eight moderately differentiated adenocarcinomas showed diffuse, strong nuclear staining of the intensity equal to normal pancreatic tissue (Figure 1b) . In contrast, nine cases of poorly differentiated and seven cases of moderately differentiated adenocarcinoma exhibited diffuse to focal weak staining (Figure 1c) . Markedly anaplastic nuclei were often negative for pp32 expression. The intensity of staining in metastatic carcinoma in lymph nodes was focal and weaker when compared to the corresponding primary tumor (Figure 1d ). The results of immunohistochemical staining are summarized in Table 1 .
A unique pattern of pp32 expression was observed in intraductal papillary mucinous neoplasms. Areas of low-grade dysplasia showed strong nuclear staining in basally located nuclei, whereas areas of moderate dysplasia showed loss of nuclear staining and faint cytoplasmic positivity (Figure 2a and b) . We observed pp32 specific staining in pancreatic intraepithelial neoplasia lesions independent of degree of the dysplasia (Figure 2c and d) .
Analysis of pp32 Protein Expression by Immunoblot
Three out of three well to moderately differentiated pancreatic ductal adenocarcinomas showed pp32 expression while none of the poorly differentiated pancreatic ductal adenocarcinomas showed pp32 expression by immunoblot (Figure 3a) . We then analyzed five pancreatic cell lines for pp32 
Discussion
Forty percent of resected pancreatic ductal adenocarcinomas are poorly differentiated and patients with this grade disease have an average median survival of 13 months. 15 Understanding the molecular aspects of this subset of pancreatic cancers would be highly informative for our understanding of pancreatic tumorigenesis and the aggressiveness of this disease. pp32 expression has previously been shown to correlate with the differentiation status in breast and prostate cancers. 1, 2 In this study, we found that pp32 expression and intensity correlated with the differentiation status of pancreatic ductal adenocarcinomas (see Table 1 ). In general, welldifferentiated pancreatic ductal adenocarcinomas and pancreatic intraepithelial neoplasia lesions showed high expression levels of pp32; while poorly differentiated lesions had reduced expression. Similarly, intraductal papillary mucinous neoplasms with low-grade dysplasia showed strong, nuclear expression of pp32. However, there was a loss of pp32 staining in intraductal papillary mucinous neoplasms with moderate dysplasia. The later finding may reflect a higher malignant potential of intraductal papillary mucinous neoplasms versus pancreatic intraepithelial neoplasia lesions. Furthermore, these areas of moderate dysplasia may represent the first signs of progression toward malignant transformation. Future work will define whether loss of pp32 nuclear staining is a critical event in the sequence from intraductal papillary mucinous neoplasms with moderate dysplasia to intraductal papillary mucinous neoplasms with severe dysplasia/carcinoma in situ and invasive carcinoma. 16 The most intriguing and promising possibility for the reduction of pp32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms is pp32's ability to inhibit K-ras-induced transformation. [3] [4] [5] Since the majority of pancreatic ductal adenocarcinomas have an activating K-ras mutation and intraductal papillary mucinous neoplasms with moderate dysplasia have a greater likelihood to harbor K-ras mutations compared to intraductal papillary mucinous neoplasms with mild dysplasia, 17 loss of pp32 staining in intraductal papillary mucinous neoplasms with moderate dysplasia may, in theory, aid the progress of these lesions to invasive carcinoma.
Previous work showed that pp32 overexpression negated K-ras-dependent tumor formation in mice and also inhibited K-ras mRNA expression. Moreover, ablation of pp32 expression accelerated K-ras dependent tumor formation and increased K-ras expression. 5 In cell culture models, it was shown that pp32 could inhibit K-ras transformation in cooperation with a number of nuclear oncogenes including c-myc, c-jun, and E1A. 4 This provides evidence that pp32 expression may be able to inhibit K-ras, dependent transformation in a heterogeneous genetic background found in most pancreatic tumors.
Introduction of pp32 expression into a poorly differentiated pancreatic cancer cell line (MiaPaCa2) that has a functional K-ras mutation underscored the importance of this molecule. Future studies will reveal the exact molecular mechanism in which pp32 expression arrested this poorly differentiated pancreatic cell line into the G 1 /G 0 phase of the cell cycle and caused an initial phenotypic effect on cell survival (Figure 4) . In brief, expression of pp32 in MiaPaCa2 cells may have regulated: (1) transcriptional networks important for proliferation and cell survival as part of the INHAT complex; 11, 13 (2) mRNA stability of important transcripts through its interaction with Hur; 8, 9 and (3) pp32's ability to bind to the phosphorylated form of Rb. 6 Together these findings suggest that a change in pp32 expression levels may be an important contributor to tumorigenesis and thus a plausible therapeutic target in poorly differentiated pancreatic ductal adenocarcinomas. It is intriguing to hypothesize that pp32 upregulation in poorly differentiated pancreatic ductal adenocarcinomas may directly signal cancer cells to behave less aggressively. 5, 13 Studies correlating pp32 status with clinical outcome and exploring the role of this multidimensional molecule in pancreatic tumorigenesis are currently ongoing.
